

VESTECK, Inc. Closes \$5.95 M Series A Preferred equity round

NEWS PROVIDED BY

VESTECK, Inc. →

Jan 04, 2022, 16:14 ET

WEST CHESTER, Pa., Jan. 4, 2022 /PRNewswire/ -- VESTECK, Inc. is pleased to announce the final closing of their \$5.95M Series A financing, which includes conversion of all existing convertible notes.

The A round was led by Florida based New World Angels (<https://www.newworldangels.com/>), followed by DeepWork Capital (<https://www.deepworkcapital.com/>) and Ocean Azul Partners (<https://oceanazulpartners.com/>).

VESTECK received significant support from Philadelphia area investors Ben Franklin Technology Partners (<https://benfranklin.org>), BioAdvance (<https://www.bioadvance.com/>), Robinhood Ventures (<https://www.robinhoodventures.com/>) and Angel Star Ventures (<https://angelstarventures.com/>).

VESTECK CEO, Joe Rafferty stated "this was targeted as a \$3.5M Series A preferred equity round, to bring in over \$5.9M, is a powerful endorsement of the VESTECK team and technology!"

These Series A funds will be used to support the manufacturing of products, pre-clinical testing and completion of in human procedures, prior to our clinical study for FDA clearance.

VESTECK has designed a platform technology comprised of 6 devices that integrate the delivery of nitinol sutures into a catheter, improving clinical outcomes for endovascular aortic aneurysm patients.

Dr. David H. Deaton, Chief Medical Officer, says, "Suture-Tight will become the standard of care in aortic aneurysm repair."

Vesteck expects to bring significant incremental revenue to an aortic repair market projected to be over \$4.5B by 2028.

About Vesteck Inc.:

VESTECK, Inc. (www.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets. Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significant global challenge for physicians and patients.

VESTECK was represented by Kevin M. Granahan of Fox Rothschild LLP

MEDIA CONTACTS: VESTECK, Inc. CEO, Joe Rafferty, J.Rafferty@VESTECK.com 610-457-7324

SOURCE VESTECK, Inc.